Abstract library

3 results for "Polus".
#1235 The Belgian DNET Registry: A Prospective, National, Web-Based Registry of Digestive Neuro-Endocrine Tumours (NET). Status After 2 Years of Inclusion.
Introduction: NET are rare neoplasms. The Belgian Group of Digestive Oncology created a web-based registry to have an overview on incidence, diagnosis and therapies performed in Belgian pts. The DNET registry was launched in 01/2012.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof. Dr. Ivan Borbath
Keywords: Registry, Belgium
#1077 Signs of Carcinoid Heart Disease on Staging CT: Which Predictors are Helpful?
Introduction: In patients with functionally active neueroendocrine neoplasms (NEN) carcinoid heart disease presenting primarily with tricuspid valve regurgitation (TR) is associated with high morbidity and mortality. Early diagnosis is crucial to improve prognosis.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. med. Alexander Baur
Authors: Baur A, Kunz F, Pschowski R, Röpke T, ...
#1284 Pharmacokinetic (PK) Differences Between Subcutaneous and Intramuscular Administration of Lanreotide: Results from a Phase I Study
Introduction: Data have shown that 38% of intended gluteal intramuscular (IM) injections with long-acting release octreotide were mistakenly given subcutaneously (SC); in carcinoid syndrome patients, this significantly increased the rate of flushing (P=0.005; Boyd 2013, Pancreas). Lanreotide depot(LD) recently became FDA-approved for the treatment of gastroenteropancreatic neuroendocrine tumors (120 mg Q4W) as a deep SC injection.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Manon A, Wolin E, Chassaing C, Lewis A, ...